Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 06/19/2015 - 04/20/2018

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Insomnia has long been considered to be a symptom of psychiatric illness. This point of view has shifted and it is now codified into several classification systems. One classification is that insomnia is to be considered a disorder in its own right. On the other hand, when insomnia occurs concurrently with other disorders it is to be considered a comorbid disorder (vs. secondary insomnia). This change has occurred primarily as a result of mounting evidence that insomnia: 1) is a risk factor for first episode depression, 2) often occurs before depression (potentially as a prodrome), 3) persists despite treatment response with antidepressant therapies, 4) is a risk factor for recurrence of depression, 5) may be successfully treated in the context of depression, and 6) treatment, at least treatment with CBT-I, appears to substantially affect the trajectory of depressive illness. Further, there is additional evidence that insomnia (and nightmares) represent a specific risk factor for suicidality (ideation, attempts, and death). This session will provide a comprehensive overview regarding sleep and depression and sleep and suicide.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Learning Objectives

  1. Determine the relationship between insomnia and major depressive disorder (MDD) in respect to a symptom versus a co-occurring disorder.
  2. Understand the available evidence for insomnia as a co-occurring disorder with MDD.
  3. Describe the impact that insomnia treatment has on response to treatment for and remission of MDD.
  4. Discuss the impact of insomnia on completed suicides.

Continuing Education Credit and Disclosures

Activity Dates: 06/19/2015 - 04/20/2018
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-15-007-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.10 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-15-007-H01-P (1.0 contact hours).

Grant Support

This activity is supported by an educational grant from Merck.